Omalizumab is a monoclonal anti-immunoglobulin E (IgE) antibody used to treat asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy. Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE).
- Mechanism
- Curator reviewed · 5 references
IgE antibodies have been implicated in several immune-mediated diseases, including allergic hypersensitivity reactions and asthma. IgE binds to the high-affinity IgE receptor Fc-epsilon-RI typically found on inflammatory cells such as eosinophils, mast cells, and basophils. IgE binding to Fc-epsilon-RI initiates a downstream cascade that releases pro-inflammatory mediators.
Omalizumab is an IgE-neutralizing antibody: It selectively binds to the C-epsilon-3 locus of IgE, the domain at which IgE binds to Fc-epsilon-RI to mediate its actions. Omalizumab works to lower circulating free IgE levels and prevent IgE from interacting with Fc-epsilon-RI, which can also lead to the reduced expression of Fc-epsilon-RI.
- Primary indication
- Omalizumab is indicated for: - the treatment of patients six years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen...Curator reviewed · 5 structured indications
- Formula / weight
- 149000.0 Da (approximate)
- First approval
- Canada, 2004 · United States, 2003 · European Union, 2020
- Also known as
- RHUMAB-E25
- Code names
- ADL-018 · CMAB007 · CT-P39 · IGE25 · RG-3648
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Omalizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account